Literature DB >> 28873013

Involvement of the specific nucleolar protein SURF6 in regulation of proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts.

Anastasiia Moraleva1, Charalambos Magoulas2, Mikhail Polzikov1, Sabine Hacot3, Hichem C Mertani3, Jean-Jacques Diaz3, Olga Zatsepina1,3.   

Abstract

The nucleolar proteins which link cell proliferation to ribosome biogenesis are regarded to be potentially oncogenic. Here, in order to examine the involvement of an evolutionary conserved nucleolar protein SURF6/Rrp14 in proliferation and ribosome biogenesis in mammalian cells, we established stably transfected mouse NIH/3T3 fibroblasts capable of conditional overexpression of the protein. Cell proliferation was monitored in real-time, and various cell cycle parameters were quantified based on flow cytometry, Br-dU-labeling and conventional microscopy data. We show that overexpression of SURF6 accelerates cell proliferation and promotes transition through all cell cycle phases. The most prominent SURF6 pro-proliferative effects include a significant reduction of the population doubling time, from 19.8 ± 0.7 to 16.2 ± 0.5 hours (t-test, p < 0.001), and of the length of cell division cycle, from 17.6 ± 0.6 to 14.0 ± 0.4 hours (t-test, p < 0.001). The later was due to the shortening of all cell cycle phases but the length of G1 period was reduced most, from 5.7 ± 0.4 to 3.8 ± 0.3 hours, or by ∼30%, (t-test, p < 0.05). By Northern blots and qRT-PCR, we further showed that the acceleration of cell proliferation was concomitant with an accumulation of rRNA species along both ribosomal subunit maturation pathways. It is evident, therefore, that like the yeast homologue Rrp14, mammalian SURF6 is involved in various steps of rRNA processing during ribosome biogenesis. We concluded that SURF6 is a novel positive regulator of proliferation and G1/S transition in mammals, implicating that SURF6 is a potential oncogenic protein, which can be further studied as a putative target in anti-cancer therapy.

Entities:  

Keywords:  SURF6; cell cycle; mouse NIH/3T3 fibroblasts; nucleolus; proliferation; rRNA processing; ribosome biogenesis

Mesh:

Substances:

Year:  2017        PMID: 28873013      PMCID: PMC5638364          DOI: 10.1080/15384101.2017.1371880

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  54 in total

Review 1.  Analysis of the cell cycle and a method employing synchronized cells for study of protein expression at various stages of the cell cycle.

Authors:  R E Uzbekov
Journal:  Biochemistry (Mosc)       Date:  2004-05       Impact factor: 2.487

2.  Overexpression of ribosomal RNA in cumulus cells of patients with polycystic ovary syndrome.

Authors:  Mikhail Polzikov; Sergey Yakovenko; Julia Voznesenskaya; Maria Troshina; Olga Zatsepina
Journal:  J Assist Reprod Genet       Date:  2012-07-07       Impact factor: 3.412

3.  The SURF-6 protein is a component of the nucleolar matrix and has a high binding capacity for nucleic acids in vitro.

Authors:  C Magoulas; O V Zatsepina; P W Jordan; E G Jordan; M Fried
Journal:  Eur J Cell Biol       Date:  1998-02       Impact factor: 4.492

Review 4.  Emerging roles of nucleolar and ribosomal proteins in cancer, development, and aging.

Authors:  Hitomi Takada; Akira Kurisaki
Journal:  Cell Mol Life Sci       Date:  2015-07-24       Impact factor: 9.261

Review 5.  The relationship between the nucleolus and cancer: Current evidence and emerging paradigms.

Authors:  Ines Orsolic; Deana Jurada; Nick Pullen; Moshe Oren; Aristides G Eliopoulos; Sinisa Volarevic
Journal:  Semin Cancer Biol       Date:  2015-12-23       Impact factor: 15.707

Review 6.  Targeting the nucleolus for cancer intervention.

Authors:  Jaclyn E Quin; Jennifer R Devlin; Donald Cameron; Kate M Hannan; Richard B Pearson; Ross D Hannan
Journal:  Biochim Biophys Acta       Date:  2014-01-02

7.  PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis.

Authors:  Jiadong Wang; Justin Wai-chung Leung; Zihua Gong; Lin Feng; Xiaobing Shi; Junjie Chen
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

8.  A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types.

Authors:  Jinger Xie; Ayyappan Nair; Terry W Hermiston
Journal:  Toxicol In Vitro       Date:  2007-09-06       Impact factor: 3.500

9.  Mutant loxP vectors for selectable marker recycle and conditional knock-outs.

Authors:  H Arakawa; D Lodygin; J M Buerstedde
Journal:  BMC Biotechnol       Date:  2001-09-26       Impact factor: 2.563

Review 10.  Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

Authors:  Elisa Brighenti; Davide Treré; Massimo Derenzini
Journal:  Oncotarget       Date:  2015-11-17
View more
  5 in total

1.  Rrp14 controls rRNA transcription via facilitating the translocation of Pol5 into the nucleolus.

Authors:  Zhen Lin; Haiyan Liu; Hongzhi Chen; Hongshi Cao; Xiaochang Liu; Haichao Zhu; Lu Zhao; Zhiming Chen
Journal:  Cell Cycle       Date:  2022-01-02       Impact factor: 4.534

2.  The Influence of the Polymer Amount on the Biological Properties of PCL/ZrO₂ Hybrid Materials Synthesized via Sol-Gel Technique.

Authors:  Michelina Catauro; Elisabetta Tranquillo; Michela Illiano; Luigi Sapio; Annamaria Spina; Silvio Naviglio
Journal:  Materials (Basel)       Date:  2017-10-17       Impact factor: 3.623

3.  Compositional adaptability in NPM1-SURF6 scaffolding networks enabled by dynamic switching of phase separation mechanisms.

Authors:  Mylene C Ferrolino; Diana M Mitrea; J Robert Michael; Richard W Kriwacki
Journal:  Nat Commun       Date:  2018-11-29       Impact factor: 14.919

Review 4.  Nucleophosmin in Its Interaction with Ligands.

Authors:  Ilaria Cela; Adele Di Matteo; Luca Federici
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

5.  Eukaryotic Ribosome Biogenesis: The 40S Subunit.

Authors:  A A Moraleva; A S Deryabin; Yu P Rubtsov; M P Rubtsova; O A Dontsova
Journal:  Acta Naturae       Date:  2022 Jan-Mar       Impact factor: 2.204

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.